» Articles » PMID: 35887519

EASIX, Modified EASIX and Simplified EASIX As an Early Predictor for Intensive Care Unit Admission and Mortality in Severe COVID-19 Patients

Overview
Journal J Pers Med
Date 2022 Jul 27
PMID 35887519
Authors
Affiliations
Soon will be listed here.
Abstract

COVID-19 receives a lot of attention due to its threat to global public health. Research is ongoing to find universal methods to assess the baseline health status of a patient to determine prognosis and management strategies. This study aims to assess the predictive potential of the EASIX (Endothelial Activation and Stress Index) and two of its modifications (mEASIX and sEASIX) in terms of the need for admission to the ICU (intensive care unit), the use of IMV (invasive mechanical ventilation) and death due to COVID-19. The medical data of 370 severely ill patients hospitalised in the COVID-19 departments of the Regional Specialist Hospital in Wroclaw (Poland), including the ICU, were analysed retrospectively. The mortality rate in the group studied was 65.7% (243 cases). In the case of all three indices, EASIX, mEASIX and sEASIX, there was a statistically significant correlation between the need for admission to the ICU (p = 0.026, p = 0.019, p = 0.001, respectively) and the risk of death (p < 0.001). In terms of the risk of death, the high values of the assessed indices (EASIX ≥ 2.36, mEASIX ≥ 704.03, sEASIX ≥ 3.81) were characterised by low sensitivity (≤40%), high specificity (approximately 90%) and low NPV (negative predictive value) (approximately 40%) with high PPV (positive predictive value) (approximately 80%). Due to the ease of implementation and the low cost of performing basic laboratory tests, the above-mentioned indices can be used as an additional, but not universal tool for the initial assessment of the health condition of patients admitted to the hospital.

Citing Articles

Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy.

Hunutlu F, Oztop H, Gursoy V, Ersal T, Elgun E, Yavuz S Diagnostics (Basel). 2025; 15(2).

PMID: 39857069 PMC: 11764177. DOI: 10.3390/diagnostics15020185.


Association between EASIX and acute kidney injury in critically ill cancer patients.

Deng F, Lin J, Lin H BMC Nephrol. 2024; 25(1):453.

PMID: 39696015 PMC: 11653550. DOI: 10.1186/s12882-024-03887-2.


Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients.

Gavriilaki E, Demosthenous C, Evangelidis P, Bousiou Z, Batsis I, Vardi A Int J Mol Sci. 2024; 25(20).

PMID: 39456810 PMC: 11507105. DOI: 10.3390/ijms252011028.


Association between Age-Adjusted Endothelial Activation and Stress Index and Intensive Care Unit Mortality in Patients with Severe COVID-19.

Jeong J, Heo M, Park S, Lee S, Park O, Kim T Tuberc Respir Dis (Seoul). 2024; 87(4):524-531.

PMID: 39044336 PMC: 11468444. DOI: 10.4046/trd.2024.0081.


Association Between Endothelial Activation and Stress Index and 28-Day Mortality in Septic ICU patients: a Retrospective Cohort Study.

Xu H, Ye Y, Xue F, Wu J, Suo Z, Zhang H Int J Med Sci. 2023; 20(9):1165-1173.

PMID: 37575274 PMC: 10416722. DOI: 10.7150/ijms.85870.


References
1.
Li Y, Ashcroft T, Chung A, Dighero I, Dozier M, Horne M . Risk factors for poor outcomes in hospitalised COVID-19 patients: A systematic review and meta-analysis. J Glob Health. 2021; 11:10001. PMC: 7980087. DOI: 10.7189/jogh.11.10001. View

2.
Bermejo-Martin J, Almansa R, Torres A, Gonzalez-Rivera M, Kelvin D . COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction. Cardiovasc Res. 2020; 116(10):e132-e133. PMC: 7314234. DOI: 10.1093/cvr/cvaa140. View

3.
Rorat M, Jurek T, Simon K, Guzinski M . Value of quantitative analysis in lung computed tomography in patients severely ill with COVID-19. PLoS One. 2021; 16(5):e0251946. PMC: 8136668. DOI: 10.1371/journal.pone.0251946. View

4.
Zhang Z, Hou Y, Li D, Li F . Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020; 80(6):441-447. PMC: 7256350. DOI: 10.1080/00365513.2020.1768587. View

5.
Kalicinska E, Szymczak D, Zinczuk A, Adamik B, Smiechowicz J, Skalec T . Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study. Cells. 2021; 10(6). PMC: 8224622. DOI: 10.3390/cells10061293. View